Nello Mainolfi - May 12, 2021 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role: Chief Executive Officer, Director
Signature: /s/ Bruce Jacobs, as Attorney-in-Fact
Stock symbol: KYMR
Transactions as of: May 12, 2021
Transactions value $: -$395,527
Form type: 4
Date filed: 5/14/2021, 05:20 PM
Next filing: May 19, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KYMR	Common Stock	Options Exercise	$17.1K	+8.25K	+2.08%	$2.08^*	405K	May 12, 2021	Direct
transaction	KYMR	Common Stock	Sale	-$413K	-8.25K	-2.03%	$50.05	397K	May 12, 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KYMR	Stock Option (Right to Buy)	Options Exercise	$0	-8.25K	-3.67%	$0.00	216K	May 12, 2021	Common Stock	8.25K	$2.08	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3	The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.